AR and prostate carcinoma: Since AR plays an essential role in the onset and progression of prostate cancer, AR degradation leads to mitotic arrest in prostate cancer cells treated with low dose 2-methoxyestradiol (2-ME, an endogenous estrogen metabolite) [32].